Catheter Precision Announces the Start of Enrollment for the LockeT Compare Study
Catheter Precision (NYSE:VTAK) has initiated enrollment in the LockeT Compare Study, with the first three patients already enrolled. This single-center, physician-initiated study aims to evaluate the safety profile of the LockeT suture retention device compared to internal closure devices.
The study will enroll up to 100 patients and focuses on addressing groin complications after cardiac catheter procedures. Previous clinical data for LockeT has demonstrated safety, effectiveness, and cost reduction benefits while maintaining existing hospital workflows. The device creates hemostasis externally and may potentially reduce thrombotic episodes compared to internal closure mechanisms.
Catheter Precision (NYSE:VTAK) ha avviato l'arruolamento nello studio LockeT Compare: i primi tre pazienti sono gi脿 stati inclusi. Questo studio monocentrico, promosso da medici, ha l'obiettivo di confrontare il profilo di sicurezza del dispositivo di ritenzione a sutura LockeT con i dispositivi di chiusura interni.
Lo studio prevede l'arruolamento fino a 100 pazienti e si concentra sulla riduzione delle complicanze in regione inguinale dopo procedure cardiache di catheterismo. Dati clinici precedenti su LockeT hanno mostrato sicurezza, efficacia e un potenziale risparmio sui costi, senza alterare i flussi di lavoro ospedalieri esistenti. Il dispositivo ottiene l鈥檈mostasi in modo esterno e potrebbe ridurre gli episodi trombotici rispetto ai meccanismi di chiusura interni.
Catheter Precision (NYSE:VTAK) ha iniciado el reclutamiento en el estudio LockeT Compare; ya se han incluido los tres primeros pacientes. Este estudio unic茅ntrico, promovido por m茅dicos, pretende evaluar el perfil de seguridad del dispositivo de retenci贸n por sutura LockeT frente a los dispositivos de cierre internos.
El estudio planea reclutar hasta 100 pacientes y se enfoca en abordar las complicaciones inguinales tras procedimientos card铆acos de cateterismo. Datos cl铆nicos previos sobre LockeT han demostrado seguridad, eficacia y reducci贸n de costes, manteniendo los flujos de trabajo hospitalarios existentes. El dispositivo logra la hemostasia de forma externa y podr铆a reducir los episodios tromb贸ticos en comparaci贸n con los mecanismos de cierre internos.
Catheter Precision (NYSE:VTAK)臧� LockeT Compare 鞐瓣惮鞚� 頇橃瀽 霌彪鞚� 鞁滌瀾頄堨溂氅�, 觳� 靹� 氇呾潣 頇橃瀽臧� 鞚措 霌彪霅橃棃鞀惦媹雼�. 鞚� 雼澕 旮瓣磤鞚� 鞚橂歆� 欤茧弰 鞐瓣惮電� 雮措秬 韽愳噭 鞛レ箻鞕� 牍勱祼頃� LockeT 氪夗暕 鞙犾 鞛レ箻鞚� 鞎堨爠靹� 頂勲頃�鞚� 韽夑皜頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞐瓣惮電� 斓滊寑 100氇�鞚� 頇橃瀽毳� 霌彪頃� 鞓堨爼鞚措┌ 鞁灔 旃错厡韯� 鞁滌垹 頉� 靹滍槣攵� 頃╇硲歃濎潉 雼る（電� 雿� 欷戩爯鞚� 霊‰媹雼�. 旮办〈 LockeT鞚� 鞛勳儊 雿办澊韯半姅 鞎堨爠靹�, 須臣靹� 氚� 牍勳毄 鞝堦皭 須臣毳� 氤挫棳欤检棃瓿�, 氤戩洂 鞛戩梾 頋愲鞚� 氤�瓴巾晿歆� 鞎婌晿鞀惦媹雼�. 鞚� 鞛レ箻電� 鞕鸽秬鞐愳劀 歆�順堨潉 鞝滉车頃橂┌ 雮措秬 韽愳噭 氚╈嫕鞐� 牍勴暣 順堨爠 氚滌儩鞚� 欷勳澕 臧�電レ劚鞚� 鞛堨姷雼堧嫟.
Catheter Precision (NYSE:VTAK) a lanc茅 le recrutement pour l'茅tude LockeT Compare : les trois premiers patients sont d茅j脿 inclus. Cette 茅tude monocentrique, initi茅e par des m茅decins, vise 脿 茅valuer le profil de s茅curit茅 du dispositif de maintien par suture LockeT par rapport aux dispositifs de fermeture internes.
L'茅tude pr茅voit d'inclure jusqu'脿 100 patients et se concentre sur la gestion des complications inguinales apr猫s des proc茅dures cardiaques par cath茅t茅risme. Les donn茅es cliniques ant茅rieures sur LockeT ont d茅montr茅 s茅curit茅, efficacit茅 et r茅duction des co没ts, tout en pr茅servant les flux de travail hospitaliers existants. Le dispositif assure l'h茅mostase de fa莽on externe et pourrait r茅duire les 茅pisodes thrombotiques par rapport aux m茅canismes de fermeture internes.
Catheter Precision (NYSE:VTAK) hat mit der Rekrutierung f眉r die LockeT Compare-Studie begonnen; die ersten drei Patienten wurden bereits eingeschlossen. Diese einzelzentren-, arztinitiierte Studie zielt darauf ab, das Sicherheitsprofil der LockeT-Nahthaltevorrichtung im Vergleich zu internen Verschlussvorrichtungen zu bewerten.
Die Studie wird bis zu 100 Patienten einschlie脽en und konzentriert sich auf die Vermeidung von Leistenkomplikationen nach kardialen Katheterverfahren. Fr眉here klinische Daten zu LockeT haben Sicherheit, Wirksamkeit und Kostenvorteile gezeigt, ohne bestehende Krankenhausabl盲ufe zu beeintr盲chtigen. Das Ger盲t erzielt die H盲mostase extern und k枚nnte im Vergleich zu internen Verschlussmechanismen thrombotische Ereignisse reduzieren.
- Initial enrollment of first three patients successfully completed
- Study will provide comparative safety data for LockeT device
- Previous clinical data shows product is safe and reduces procedural costs
- Device maintains existing hospital workflows without requiring changes
- Study limited to single center
- Complete enrollment of 100 patients still pending
First patients have been enrolled
Fort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the LockeT Compare Study has enrolled its first three patients.
The LockeT Compare Study is a single center, physician-initiated study that will enroll up to 100 patients and evaluate the safety profile of the LockeT suture retention device compared to internal closure devices. Groin complications after a cardiac catheter procedure, such as atrial fibrillation, are common and can range from small bruising to serious events such as embolism. To date, LockeT clinical data has shown that the product is safe, effective and reduces procedural cost without changing current hospital practices and workflows.
鈥淓ffective groin management at the access site after a cardiac catheter procedure, is just as important as the procedure outcomes,鈥� said David Jenkins, CEO of Catheter Precision. 鈥淲e have successfully shown that LockeT creates hemostasis as an external device and believe that this study will also show that there is a reduction in thrombotic episodes compared to closure devices that have an internal closure mechanism, thus improving patient safety.鈥�
About LockeT
Catheter Precision鈥檚 is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as 鈥渂elieve,鈥� 鈥渁nticipate,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渃an,鈥� 鈥渃ould,鈥� 鈥渃ontinue,鈥� 鈥渄epends,鈥� 鈥渆xpect,鈥� 鈥渆xpand,鈥� 鈥渇orecast,鈥� 鈥渋ntend,鈥� 鈥減redict,鈥� 鈥減lan,鈥� 鈥渞ely,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渟eek,鈥� or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. 聽These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company鈥檚 expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 鈥淩isk Factors鈥� in the Company鈥檚 Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
# # #
FAQ
What is the LockeT Compare Study by Catheter Precision (VTAK)?
How many patients have been enrolled in the VTAK LockeT Compare Study?
What are the benefits of Catheter Precision's LockeT device?
What complications does the LockeT device aim to address?
Who is leading Catheter Precision's LockeT Compare Study?
